Yong-Jiang Hei

1.0k total citations
19 papers, 768 citations indexed

About

Yong-Jiang Hei is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yong-Jiang Hei has authored 19 papers receiving a total of 768 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Yong-Jiang Hei's work include Bone health and treatments (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Prostate Cancer Treatment and Research (3 papers). Yong-Jiang Hei is often cited by papers focused on Bone health and treatments (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Prostate Cancer Treatment and Research (3 papers). Yong-Jiang Hei collaborates with scholars based in United States, Canada and United Kingdom. Yong-Jiang Hei's co-authors include Ming Zheng, Richard J. Cook, Fred Saad, Ronald Linnartz, Eric J. Small, David L. Bilhartz, Carsten Goessl, Marc Gittelman, R. Nevin Murray and Celestia S. Higano and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Diabetes.

In The Last Decade

Yong-Jiang Hei

18 papers receiving 755 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yong-Jiang Hei United States 12 442 303 207 168 143 19 768
William R. Berry United States 21 946 2.1× 538 1.8× 251 1.2× 319 1.9× 326 2.3× 56 1.3k
Jaymes Holland United States 14 299 0.7× 259 0.9× 294 1.4× 43 0.3× 143 1.0× 25 769
Philippe Lothaire Belgium 12 691 1.6× 528 1.7× 410 2.0× 99 0.6× 198 1.4× 36 1.2k
Anis Hamid United States 13 425 1.0× 206 0.7× 166 0.8× 94 0.6× 182 1.3× 54 599
Akihiko Suto Japan 15 188 0.4× 503 1.7× 285 1.4× 59 0.4× 190 1.3× 63 945
Yota Yasumizu Japan 18 367 0.8× 322 1.1× 419 2.0× 113 0.7× 180 1.3× 78 927
Guangzhou Han United States 9 352 0.8× 186 0.6× 376 1.8× 36 0.2× 216 1.5× 15 812
Ahmed Basudan Saudi Arabia 13 238 0.5× 289 1.0× 238 1.1× 34 0.2× 189 1.3× 34 643
Noelia Martínez-Jáñez Spain 15 300 0.7× 568 1.9× 202 1.0× 121 0.7× 319 2.2× 79 846

Countries citing papers authored by Yong-Jiang Hei

Since Specialization
Citations

This map shows the geographic impact of Yong-Jiang Hei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yong-Jiang Hei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yong-Jiang Hei more than expected).

Fields of papers citing papers by Yong-Jiang Hei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yong-Jiang Hei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yong-Jiang Hei. The network helps show where Yong-Jiang Hei may publish in the future.

Co-authorship network of co-authors of Yong-Jiang Hei

This figure shows the co-authorship network connecting the top 25 collaborators of Yong-Jiang Hei. A scholar is included among the top collaborators of Yong-Jiang Hei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yong-Jiang Hei. Yong-Jiang Hei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Wang, Sheng, Rong Su, Xufeng Li, et al.. (2024). BC3195, a novel ADC targeting CDH3: Preliminary results of a first-in-human phase I study in patients with advanced solid malignancies.. Journal of Clinical Oncology. 42(16_suppl). e15008–e15008.
2.
Zhang, Jian, Hong Zheng, Yunong Gao, et al.. (2019). Phase I Pharmacokinetic Study of Niraparib in Chinese Patients with Epithelial Ovarian Cancer. The Oncologist. 25(1). 19–e10. 5 indexed citations
3.
Peng, Zhi, Zhongwu Li, Jing Gao, et al.. (2015). Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer. Molecular Cancer Therapeutics. 14(11). 2634–2641. 19 indexed citations
4.
Novello, Silvia, Giorgio V. Scagliotti, Ihor Vynnychenko, et al.. (2014). Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study. Journal of Thoracic Oncology. 9(8). 1154–1161. 14 indexed citations
5.
Bass, Michael, Bin Yao, Yong-Jiang Hei, et al.. (2014). Challenges in Developing a Validated Biomarker for Angiogenesis Inhibitors: The Motesanib Experience. PLoS ONE. 9(10). e108048–e108048. 5 indexed citations
6.
Paz‐Ares, Luis, Beatrix Bálint, Richard H. De Boer, et al.. (2013). A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 8(3). 329–337. 58 indexed citations
7.
Rosen, Lee S., Lara Lipton, Timothy Price, et al.. (2013). The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer. 13(1). 242–242. 11 indexed citations
8.
9.
Berruti, Alfredo, Luigi Dogliotti, Marco Tampellini, et al.. (2006). Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. Journal of Clinical Oncology. 24(18_suppl). 8610–8610. 4 indexed citations
10.
Smith, Matthew R., Fairooz F. Kabbinavar, Fred Saad, et al.. (2005). Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology. 23(13). 2918–2925. 377 indexed citations
11.
Hirsh, Vera, N. Simon Tchekmedyian, Lee S. Rosen, Ming Zheng, & Yong-Jiang Hei. (2004). Clinical Benefit of Zoledronic Acid in Patients with Lung Cancer and OtherSolid Tumors: Analysis Based on History of Skeletal Complications. Clinical Lung Cancer. 6(3). 170–174. 52 indexed citations
12.
Hei, Yong-Jiang. (2004). Future Directions for Zoledronic Acid and New Agents for the Treatment of Bone Metastases. European Urology Supplements. 3(5). 55–62. 2 indexed citations
13.
Beehler, Blake C., Yong-Jiang Hei, Simon Chen, et al.. (2003). Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis.. PubMed. 30(2). 355–63. 28 indexed citations
14.
Hei, Yong-Jiang, et al.. (1998). Stimulation of MAP kinase and S6 kinase by vanadium and selenium in rat adipocytes. Molecular and Cellular Biochemistry. 178(1-2). 367–375. 59 indexed citations
15.
Hei, Yong-Jiang. (1998). Recent progress in insulin signal transduction. Journal of Pharmacological and Toxicological Methods. 40(3). 123–135. 11 indexed citations
16.
Marhin, Wilson W., Yong-Jiang Hei, Shaojun Chen, et al.. (1996). Loss of Rb and Myc activation co-operate to suppress cyclin D1 and contribute to transformation.. PubMed. 12(1). 43–52. 32 indexed citations
17.
Hei, Yong-Jiang, Xunsheng Chen, Steven Pelech, Jack Diamond, & John H. McNeill. (1995). Skeletal Muscle Mitogen-Activated Protein Kinases and Ribosomal S6 Kinases: Suppression in Chronic Diabetic Rats and Reversal by Vanadium. Diabetes. 44(10). 1147–1155. 21 indexed citations
18.
Hei, Yong-Jiang, Xunsheng Chen, Jack Diamond, & John H. McNeill. (1994). Distribution of MAP kinase, S6 kinase, and casein kinase II in rat tissues: activation by insulin in spleen. Biochemistry and Cell Biology. 72(1-2). 49–53. 12 indexed citations
19.
Hei, Yong-Jiang, Jack Diamond, & John H. McNeill. (1992). Alterations of G protein function in cardiac tissues from streptozotocin-induced chronic diabetic rats. General Pharmacology The Vascular System. 23(5). 889–896. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by William R. Berry Breakdown of academic impact, for papers by Jaymes Holland Breakdown of academic impact, for papers by Philippe Lothaire Breakdown of academic impact, for papers by Anis Hamid Breakdown of academic impact, for papers by Akihiko Suto Breakdown of academic impact, for papers by Yota Yasumizu Breakdown of academic impact, for papers by Guangzhou Han Breakdown of academic impact, for papers by Ahmed Basudan Breakdown of academic impact, for papers by Noelia Martínez-Jáñez
Rankless by CCL
2026